Dr. Raghavan is an internationally-renowned cancer researcher and medical oncologist and President of Levine Cancer Institute. Dr. Raghavan’s vision for the Institute is to bring cancer research and clinical innovations closer to home for patients across 33-hospital Carolinas HealthCare System by redefining the role of a traditional cancer center.
Innovating Access to Cancer Care
Since he began in April 2011, Dr. Raghavan has led the charge to eliminate natural barriers to top-quality care, such as distance to clinical and research sites, cultural barriers, access, and more. In September 2011, he launched the Institute’s first patient navigator academy, and one of the first for a health system in the country. The academy provided enhanced training to staff to help them guide cancer patients and their families through their care journey and transition oncology care to the most appropriate location for the patient. He also has been instrumental in the development of the Institute’s community-based care efforts to address demographic and geographic disparities in screening and treatment; and the acquisition of more first-in-human and Phase 2 clinical trial offerings to advance the study and treatment of cancer.
Dr. Raghavan’s clinical and research interests are focused on genitourinary cancer, cancer in the elderly, anticancer drug discovery and development, and comparative human oncology. He currently serves on the editorial board for numerous medical journals; has been a principal investigator for more than a dozen major research grants; has published more than 300 papers in peer-reviewed professional journals; and edited nine textbooks.
He is highly sought after as a consultant on cancer and currently serves on the external advisory boards of cancer centers at Washington University, University of Miami, Roswell Park Cancer Institute and Virginia Commonwealth University. He is a member of the Cancer Center Review Panel of Deutsche Krebshilfe, Germany, and Board Member of the Leukemia Lymphoma Society. Most recently, he’s been a national voice for American Society of Clinical Oncology (ASCO) advocating lawmakers end the prescription drug shortage plaguing medicine and oncology in particular. He has served as adviser for Cancer Research U.K.; adviser to the European Organization for Research and Treatment of Cancer; chair of the National Cancer Institute’s Cancer Clinical Investigations Review Committee and part of NCI’s Clinical Oncology Grants Review Study Section; and vice chairman of the Genitourinary Committee of the Southwest Oncology Group. He is a former member of the FDA Oncology Drug Advisory Committee and a former chairman of the Veterans Administration Merit Review Board in Oncology, and was joint Chair of the ASCO’s Health Disparities Advisory Group. He was elected a Fellow of the American Association for the Advancement of Science in 2007.
Prior to coming to Levine Cancer Institute, Dr. Raghavan served concurrent appointments as Chairman and Director of the Taussig Cancer Center at Cleveland Clinic and as the M. Frank and Margaret Domiter Rudy Institute (Distinguished) Chair in Translational Cancer Research. Under his leadership, the Institute progressed from a rating of #46 to #9 in U.S. News & World Report’s national ranking of top cancer hospitals. During that time he also was responsible for recruiting more than 70 top cancer professionals to the Clinic and for major initiatives like early clinical trials in genitourinary cancer, a clinical trial of circulating tumor cell assay that led to FDA approval for use as prognostic tool for prostate cancer, and the establishment of a patient navigation program for under-served African Americans.
Before joining Cleveland Clinic, Dr. Raghavan was a professor of medicine, professor of urology and chief of the Division of Oncology at the University of Southern California. He also served as associate director for clinical research at USC/Norris Comprehensive Cancer Center. He began his medical career in Australia, carrying out clinical and laboratory research in genito-urinary and lung cancers. After 10 years in Australia, he was recruited to lead the departments Solid Tumor Oncology and Investigational Therapeutics at Roswell Park Cancer Institute in Buffalo, NY, where he was also professor of medicine at the State University of New York at Buffalo. Trained in Medicine and Oncology at the University of Sydney, Australia, Dr. Raghavan received a PhD in experimental pathology from the University of London/Ludwig Institute for Cancer Research, and then completed post-doctoral studies at the University of Minnesota.